Supernus Pharmaceuticals, Inc. $SUPN Stock: Signaturefd LLC Boosts Holdings

Signaturefd LLC lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 12,566.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 66,754 shares of the specialty pharmaceutical company’s stock after purchasing an additional 66,227 shares during the quarter. Signaturefd LLC’s holdings in Supernus Pharmaceuticals were worth $2,873,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of SUPN. James Investment Research Inc. boosted its position in Supernus Pharmaceuticals by 9.0% in the third quarter. James Investment Research Inc. now owns 22,904 shares of the specialty pharmaceutical company’s stock valued at $986,000 after buying an additional 1,900 shares during the last quarter. Ellsworth Advisors LLC raised its position in Supernus Pharmaceuticals by 3.4% during the 3rd quarter. Ellsworth Advisors LLC now owns 18,121 shares of the specialty pharmaceutical company’s stock worth $780,000 after buying an additional 601 shares during the last quarter. Juncture Wealth Strategies LLC lifted its stake in Supernus Pharmaceuticals by 5.8% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company’s stock valued at $292,000 after acquiring an additional 374 shares during the period. Versant Capital Management Inc lifted its stake in Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $1,119,000.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $40.70 on Monday. The stock has a 50 day moving average of $43.11 and a 200 day moving average of $46.03. The stock has a market cap of $2.37 billion, a P/E ratio of -21.20, a P/E/G ratio of 1.20 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a twelve month low of $37.54 and a twelve month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same period in the previous year, the firm posted $0.40 earnings per share. The company’s revenue was up 32.4% compared to the same quarter last year. On average, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on SUPN shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, September 21st. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of “Hold” and an average target price of $63.00.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.